A Study to Inv. Safety,Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children<6 Years With T1D

Zealand Pharma logo

Zealand Pharma

Status and phase

Enrolling
Phase 3

Conditions

Hypoglycemia

Treatments

Drug: Dasiglucagon

Study type

Interventional

Funder types

Industry

Identifiers

NCT05378672
ZP4207-21052

Details and patient eligibility

About

This research study will investigate whether dasiglucagon as a rescue therapy for participants between 1 and 6 years of age works and is safe to use. In addition, the study will investigate how dasiglucagon works in the body (pharmacokinetics and pharmacodynamics). Participants will receive 1 single dose as an injection under the skin (subcutaneous, s.c.). Participants will have 3 visits with the study team. For each participant, the study will last up to 84 days.

Full description

This trial will use a single-administration, open-label trial design to assess the ability of a single SC injection of dasiglucagon to increase plasma glucose in pediatric children with T1D with hypoglycemia. A total of 8 children will be included; 4 children receiving a dose of 0.3 mg and 4 children receiving a dose of 0.6 mg. Of the 4 children receiving 0.3 mg, at least 2 children must be below 2 years at screening. The 2 additional children receiving 0.3 mg should weigh below 15 kg at screening and should preferably be below 4 years at screening. For children receiving the 0.6 mg dose, all must be above 2 years at screening. Before an eligible child is dosed, the dose level (0.6 mg or 0.3 mg) must be confirmed by the sponsor. Each child will be dosed after the safety assessment of the preceding child has been completed and assessed by the Trial Safety Group. The trial will include the following visits A screening visit (Visit 1) in the period from Day - 50 to Day - 29 (pre-treatment visit) A dosing visit (Visit 2), Day 1 (day of single dosing with investigational medicinal product [IMP]) A Safety follow-up visit (Visit 3) at Day 29 +5 days (the end-of-trial visit) The primary endpoint of the trial is plasma glucose change from baseline at 30 minutes after IMP injection or at the time of rescue by intravenous glucose. Pharmacodynamics (PD) i.e., plasma glucose will be assessed at baseline and 15 and 30 minutes after dosing, while the glucose levels will be monitored by continuous glucose monitoring and by a plasma glucose analyzer during the dosing visit (Visit 2). Pharmacokinetics (PK) will be assessed throughout a 300-minute period at the dosing visit (Visit 2). Safety will be assessed prior to dosing and throughout a 300-minute period after dosing and again at the follow-up visit.

Enrollment

8 estimated patients

Sex

All

Ages

1 to 5 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants who are confirmed as having T1D based on medical history and are receiving daily insulin therapy via insulin pump
  • Body weight greater than 8 kg
  • Further inclusion criteria apply

Exclusion criteria

  • Known or suspected allergy to the IMP or related products
  • Any condition that in the investigators opinion may result in diminished hepatic glycogen stores (eg prolonged fasting (more than 24 hours) at Visit 2
  • History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema)
  • History of hypoglycemia unawareness
  • History of hypoglycemic events associated with seizures
  • Further exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

8 participants in 1 patient group

Dasiglucagon 0.6 mg
Experimental group
Description:
Participants will receive a single dose of dasiglucagon.
Treatment:
Drug: Dasiglucagon

Trial contacts and locations

2

Loading...

Central trial contact

Clinical Operations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems